Physician profile
Claudio Milite
NPI 1396761458
$3,337.88
in general payments reported to CMS, 2019-2025
26 companies · $883 in 2025
The $883 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $115 · 2021: $749 · 2022: $206 · 2023: $133 · 2024: $790 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,695 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,694.52 |
| Education | $112.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $424.84 | 2019-2024 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $330.76 | 2021-2025 | Acthar |
| Amgen INC. | $319.45 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Travere Therapeutics, INC. | $270.44 | 2023-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $242.47 | 2019-2025 | Jynarque |
| Akebia Therapeutics INC | $226.94 | 2021-2025 | Vafseo, Auryxia |
| Fresenius USA Marketing, INC. | $210.90 | 2019-2025 | Velphoro, Velphoro |
| Vifor Pharma, INC. | $174.47 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $174.33 | 2019-2025 | |
| Novo Nordisk INC | $147.32 | 2024-2025 | Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $107.96 | 2022-2025 | |
| Ardelyx, INC. | $106.64 | 2024-2025 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $99.28 | 2019-2025 | Ultomiris |
| Lilly USA, LLC | $92.84 | 2024-2025 | Jardiance |
| Genzyme Corporation | $73.55 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $72.58 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $63.28 | 2024-2025 | Lupkynis |
| Calliditas Therapeutics US INC. | $62.31 | 2025 | Tarpeyo |
| Ani Pharmaceuticals, INC. | $22.74 | 2025 | Purified Cortrophin Gel |
| Amag Pharmaceuticals, INC. | $20.16 | 2020 | |
| Baxter Healthcare | $18.83 | 2024 | Renal - Pd |
| Ultragenyx Pharmaceutical INC. | $17.19 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.07 | 2024 | Jardiance |
| Opko Pharmaceuticals, LLC | $14.59 | 2022 | |
| Cormedix INC. | $13.73 | 2024 | Defencath |
| Mallinckrodt Enterprises LLC | $13.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claudio Milite listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.